Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Restructuring & Insolvency

Regulatory update: insolvency of a local debtor: the creditor position in Kazakhstan in the pharmaceuticals sector

Daniyar Abenov · August 2026 · 8 min read

Kazakhstan revised insolvency creditor-priority rules now affect pharmaceutical trade creditors. What foreign companies must know. Make an enquiry.

Amendments to Kazakhstan's rehabilitation and bankruptcy framework, which took effect through legislative revisions introduced in the 2023–2025 reform cycle, have materially altered the creditor position in local insolvency proceedings. For foreign pharmaceutical companies supplying Kazakh distributors or holding trade receivables against Kazakh counterparties, the changes affect both priority ranking and the procedural steps required to preserve a claim. Foreign creditors who rely on pre-amendment assumptions about the creditor queue — or who delay filing claims after insolvency proceedings open — risk finding themselves subordinated to domestic priority creditors or barred entirely from the distribution.

What changed — the amended framework for creditor claims in Kazakhstan insolvency

Under the pre-amendment framework, Kazakhstan insolvency law applied a broadly hierarchical creditor queue, with secured creditors ranking first, followed by employees and statutory priority claims, and then unsecured commercial creditors. Foreign trade creditors in the pharmaceuticals sector — typically supplying finished medicines, active pharmaceutical ingredients, or medical devices to Kazakh importers and distributors — occupied the general unsecured tier. Their position was structurally straightforward, if not generous.

The 2023–2025 amendments introduced three developments that are particularly material for foreign pharmaceutical creditors. First, the legislation reinforced the role of the rehabilitation procedure as the default entry point for distressed debtors, narrowing the circumstances in which a debtor proceeds directly to liquidation bankruptcy. This has the practical effect of lengthening the period during which a foreign creditor's claim is frozen: under rehabilitation, a moratorium on creditor enforcement typically applies from the date the court approves the rehabilitation plan, and that moratorium has, in revised practice, been applied by Kazakh courts to cross-border enforcement as well as domestic execution.

Second, the amendments expanded the categories of preferential claim that rank ahead of general unsecured creditors. Environmental remediation obligations and certain state regulatory fines — both categories relevant to pharmaceutical manufacturers holding Kazakh production licences or operating through local subsidiaries — now share a priority tier above general unsecured trade debt. For a foreign supplier without security over Kazakh assets, this effectively reduces the recovery pool available by the time distributions reach the unsecured tier.

Third, in a development specific to the pharmaceutical sector, the Ministry of Health of Kazakhstan and the Committee on Pharmaceutical Control retained — and in amended form reinforced — their authority to require the return or destruction of pharmaceutical stock held by an insolvent debtor that does not meet current registration standards. Where a foreign creditor's security interest or retention-of-title arrangement encompasses pharmaceutical stock, the regulatory overlay may limit the ability to realise that security without prior regulatory clearance.

"The rehabilitation-first model now common across EAEU member states creates a window problem for foreign creditors: the moratorium protects the debtor's position precisely when creditors need to act, and the amended Kazakh framework has extended that window." — Daniyar Abenov, Contributing Regional Analyst — Kazakhstan, Vetrov & Partners

Which foreign pharmaceutical creditors are most affected?

The changes described above affect foreign creditors differently depending on their structural position in the supply chain.

Foreign manufacturers supplying Kazakh distributors on open-account credit terms are the most exposed category. Their claims are typically unsecured trade debt, denominated in foreign currency, and not supported by any pledge over Kazakh assets. Under the revised framework, this group faces a longer moratorium period, a reduced unsecured pool, and — where the distributor also holds pharmaceutical stock — potential complications in tracing and recovering goods.

Foreign creditors operating through a Kazakh subsidiary or joint venture occupy a different position. Where the subsidiary itself is a creditor of the insolvent debtor, its claims are treated as domestic Kazakh creditor claims for procedural purposes. The foreign parent's ability to direct the subsidiary's conduct in insolvency proceedings is governed by Kazakhstan corporate law as it interacts with insolvency procedure, and there are practical constraints — including the requirement to appoint a local insolvency administrator and to file claims through established Kazakh procedural channels — that parent entities based outside Kazakhstan frequently underestimate.

Cross-border creditors with Russian or other EAEU-jurisdiction connections should also note that Kazakhstan's membership of the EAEU, while it facilitates certain trade and regulatory recognition arrangements, does not create a unified cross-border insolvency framework. Recognition of foreign creditor claims, enforcement of foreign judgments or arbitral awards as the basis for a creditor claim in Kazakh insolvency proceedings, and the interaction of Russian court orders with Kazakh insolvency procedure all require separate analysis. The Restructuring & Insolvency practice page sets out the current procedural map.

The pharmaceutical sector introduces an additional layer of regulatory exposure. The EAEU's harmonised pharmaceutical market framework — which requires medicines marketed in Kazakhstan to hold EAEU or Kazakh national registration — means that goods in transit or held by an insolvent debtor may be subject to regulatory suspension or recall irrespective of the creditor's legal title. Foreign creditors holding security over pharmaceutical stock should verify, before relying on that security, whether the stock meets current registration requirements and whether any pending regulatory action by the Committee on Pharmaceutical Control could extinguish or impair the value of the collateral.

Creditors who delay initiating their claim in Kazakh insolvency proceedings risk losing priority to later-filed preference creditors and, in some cases, may miss the filing deadline entirely — a procedural bar that Kazakh courts have, in the general run of decisions, applied strictly to foreign as well as domestic creditors. The deadline for filing a creditor claim from the date of official publication of insolvency proceedings varies by procedure type and is typically measured in weeks, not months.

What foreign creditors should do now

The practical steps available to a foreign pharmaceutical creditor depend heavily on where in the insolvency timeline the matter currently sits.

If proceedings have not yet opened: the most valuable action is a structural review of the creditor's position before a filing occurs. This means reviewing the terms of any distribution or supply agreement governing the Kazakh counterparty relationship, identifying whether any security interest — pledge, retention of title, or guarantee — has been validly perfected under Kazakh law, and assessing whether the regulatory position of the pharmaceutical goods held by the counterparty is current. A prior-to-insolvency security review is far more productive than a post-filing attempt to reconstruct a security position.

If proceedings have opened: the filing deadline is the immediate priority. As noted above, Kazakh courts generally apply filing deadlines strictly. A foreign creditor should act through Kazakh-qualified counsel who can file the claim in the required form, in the required language, and within the prescribed period. The Asset Tracing & Recovery and Enforcement of Foreign Judgments & Awards pages describe the adjacent procedural options where a creditor also holds a foreign judgment or arbitral award.

If the debtor is in rehabilitation rather than liquidation: the moratorium means direct enforcement is suspended. The creditor's focus should shift to participation in the creditors' committee, monitoring the rehabilitation plan, and — where the plan is likely to be inadequate — preparing the basis for a subsequent challenge or conversion of the proceedings to liquidation. Pharmaceutical-sector creditors should also monitor regulatory action against the debtor's licences: the loss of a pharmaceutical import or distribution licence during rehabilitation often signals that the debtor cannot trade its way back to solvency, and this information is material to creditor strategy.

Vetrov & Partners advises foreign companies on cross-border Kazakhstan–Russia matters and collaborates with Kazakhstan-qualified counsel for matters requiring Kazakh court appearances, regulatory filings, and insolvency proceedings. Our regional practice covers the full creditor-side mandate — from pre-insolvency security review through to claim filing, creditors' committee representation, and enforcement of recovered assets. Details of the Kazakhstan practice are at Kazakhstan — Restructuring & Insolvency.

Frequently asked questions

Q: What specifically changed in Kazakhstan's insolvency framework for foreign creditors? A: Kazakhstan's 2023–2025 legislative amendments to the rehabilitation and bankruptcy framework made rehabilitation the default entry procedure for distressed debtors, expanded the categories of preferential claim ranking above general unsecured debt, and reinforced regulatory authority over pharmaceutical stock held by insolvent entities. For foreign trade creditors, the combined effect is a longer moratorium period, a reduced unsecured distribution pool, and — in the pharmaceutical sector specifically — a regulatory overlay that may impair the value of security held over pharmaceutical goods. The amendments did not create a separate foreign creditor category: foreign trade creditors are treated as general unsecured creditors unless they hold validly perfected Kazakh-law security.

Q: Which types of foreign pharmaceutical creditor are most exposed under the revised rules? A: Foreign manufacturers supplying Kazakh distributors on open-account credit terms face the greatest structural exposure, as their claims are unsecured and the revised framework reduces the pool available to the unsecured tier. Foreign creditors operating through a Kazakh subsidiary are subject to Kazakh procedural requirements regardless of the parent's jurisdiction. Cross-border creditors with Russian or other EAEU connections should note that EAEU membership does not create a unified cross-border insolvency regime: recognition of foreign claims and enforcement of foreign judgments in Kazakh insolvency proceedings requires separate procedural steps. Creditors holding security over pharmaceutical stock face an additional risk: EAEU and Kazakh pharmaceutical registration requirements may limit the ability to realise that security if the goods are subject to regulatory action.

Q: What should a foreign pharmaceutical creditor do immediately on learning that a Kazakh debtor has entered insolvency proceedings? A: The immediate priority is filing a creditor claim within the statutory deadline, which is typically measured in weeks from the date of official publication and which Kazakh courts apply strictly. Filing requires Kazakh-qualified counsel who can submit the claim in the correct form and language. Simultaneously, the creditor should assess the security position — including any pledge or retention-of-title arrangement — and verify the regulatory status of any pharmaceutical stock held by the debtor. Where the creditor also holds a foreign judgment or arbitral award, the process for recognition and use of that award as the basis for a Kazakh insolvency claim requires separate procedural steps. Early instruction of local counsel with cross-border experience is the single most important step a foreign creditor can take.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry